Asthma snip from Quarterly... "In addition to demonstrating...

Asthma snip from Quarterly...

"In addition to demonstrating efficacy in pre-clinical models of GvHD and critical limb ischaemia, the Company now has compelling data for its Cymerus™ MSCs in an animal model of asthma. In a study conducted under the supervision of Associate Professor Chrishan Samuel and Dr Simon Royce at Monash University, intravenous administration of Cynata’s MSCs in animals in which a chronic allergic airways disease had been induced caused a statistically significant improvement in their symptoms. Moreover, intranasal administration of Cynata’s MSCs completely normalised the symptoms in the experimental animals. Given that the features of this model closely resemble the clinical manifestations of asthma in humans the findings in this study suggest that Cymerus™ MSCs could have a profound effect in the treatment of asthma."

This had a few excited recently, and was also a nice surprise for the long termers news wise